Abemaciclib D8
- CAS No.
- 2088650-53-5
- Chemical Name:
- Abemaciclib D8
- Synonyms
- Abemaciclib D8
- CBNumber:
- CB98019751
- Molecular Formula:
- C27H32F2N8
- Molecular Weight:
- 506.61
- MDL Number:
- MOL File:
- 2088650-53-5.mol
- MSDS File:
- SDS
Abemaciclib D8 price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0374427 | Abemaciclib-d8 99.96% | 2088650-53-5 | 1mg | $455 | 2026-06-04 | Buy |
| ChemScene | CS-0374427 | Abemaciclib-d8 99.96% | 2088650-53-5 | 5mg | $1192 | 2026-06-04 | Buy |
| Arctom | HY-16297AS | Abemaciclib-d8 99.96% | 2088650-53-5 | 1mg | $399 | 2026-05-26 | Buy |
| Arctom | HY-16297AS | Abemaciclib-d8 99.96% | 2088650-53-5 | 5mg | $1045 | 2026-05-26 | Buy |
Abemaciclib D8 Chemical Properties, Uses, Production
Uses
Isotope labelled Abemaciclib is a potent and selective inhibitor of cyclin-dependent kinases, CDK4 and CDK6, as a method to inhibit the proliferation of cancer cells.
Biological Activity
Abemaciclib-d8 (LY2835219-d8) is the deuterium labeled Abemaciclib. Abemaciclib (LY2835219) is a selective CDK4/6 inhibitor with IC50 values of 2 nM and 10 nM for CDK4 and CDK6, respectively. Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Ku BM, et al. The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma. Oncotarget.2016 Mar 22;7(12):14803-13. [3]. Yadav V, et al. The CDK4/6 inhibitor LY2835219 overcomes PLX4032 resistance resulting from MAPK reactivation and cyclin D1 upregulation. Mol Cancer Ther. 2014 Oct;13(10):2253-63. [4]. Gelbert LM, et al. Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with NSC 613327. Invest New Drugs. 2014 Oct;32(5):825-37.
Abemaciclib D8 Preparation Products And Raw materials
Raw materials
Preparation Products
Abemaciclib D8 Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| BOC Sciences | +1-631-485-4226 | inquiry@bocsci.com | United States | 19935 | 58 |
| Guangzhou Younan Technology Co., Ltd | 020-82000279 18988941452 | YN_research@163.com | China | 2984 | 58 |
| SHENZHEN PHYSTANDARD BIO-TECH CO.,LTD | 0755-83725350 13380397412 | 3001280422@qq.com | China | 10000 | 58 |
| Manhag Testing Technology Co., Ltd | 400-818 0104 18918165978 | yanyan.guo@bestown.net.cn | China | 7770 | 58 |
| LGC Science (Shanghai) Ltd. | 17717235263 | offer.de@lgcgroup.com | China | 19036 | 58 |
| Shanghai Haohong Scientific Co., Ltd. | 400-8210725 4008210725 | malulu@leyan.com | China | 39319 | 58 |
| Cato Research Chemicals Inc. | 81960175 18933936954 | 2853283383@qq.com | China | 11418 | 58 |
| Hubei YoungXin Pharmaceutical Tech Co.,Ltd. | 0714-3999001 19171453112 | 2881391661@qq.com | China | 10000 | 58 |
| Aladdin Scientific | tp@aladdinsci.com | United States | 50089 | 58 |
